Tarsus Pharmaceuticals, Inc.
TARS
$58.85
$2.243.96%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 381.14M | 407.92M | 291.38M | 316.95M | 323.58M |
| Total Receivables | 60.24M | 64.15M | 48.06M | 30.30M | 30.84M |
| Inventory | 3.87M | 2.71M | 2.62M | 2.85M | 2.20M |
| Prepaid Expenses | 29.17M | 6.00M | 14.65M | 7.02M | 5.97M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 474.43M | 480.77M | 356.71M | 357.12M | 362.59M |
|
|
|||||
| Total Current Assets | 474.43M | 480.77M | 356.71M | 357.12M | 362.59M |
| Net Property, Plant & Equipment | 3.41M | 3.18M | 2.87M | 4.20M | 4.21M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 7.85M | 8.09M | 8.33M | 8.57M | 3.67M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 6.31M | 5.71M | 6.09M | 3.42M | 3.38M |
| Total Assets | 494.99M | 500.75M | 376.99M | 376.30M | 376.84M |
|
|
|||||
| Total Accounts Payable | 28.08M | 28.38M | 27.74M | 26.82M | 26.65M |
| Total Accrued Expenses | 16.74M | 13.85M | 19.14M | 15.72M | 8.51M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 317.00K | 384.00K | 608.00K | 631.00K | 605.00K |
| Total Finance Division Other Current Liabilities | 45.12M | 43.69M | 33.12M | 22.70M | 15.80M |
| Total Other Current Liabilities | 45.12M | 43.69M | 33.12M | 22.70M | 15.80M |
| Total Current Liabilities | 90.25M | 86.31M | 80.61M | 65.87M | 51.57M |
|
|
|||||
| Total Current Liabilities | 90.25M | 86.31M | 80.61M | 65.87M | 51.57M |
| Long-Term Debt | 72.13M | 71.98M | 71.85M | 71.71M | 71.58M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | 1.24M | 1.45M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 162.38M | 158.29M | 152.46M | 138.82M | 124.60M |
|
|
|||||
| Common Stock & APIC | 738.24M | 727.70M | 584.57M | 574.24M | 566.10M |
| Retained Earnings | -405.67M | -385.33M | -360.21M | -337.10M | -313.68M |
| Treasury Stock & Other | 39.00K | 85.00K | 179.00K | 346.00K | -176.00K |
| Total Common Equity | 332.61M | 342.46M | 224.53M | 237.48M | 252.25M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 332.61M | 342.46M | 224.53M | 237.48M | 252.25M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 332.61M | 342.46M | 224.53M | 237.48M | 252.25M |
|
|
|||||